This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study of ENMD-2076 in Ovarian Clear Cell Cancers

This study is currently recruiting participants.
See Contacts and Locations
Verified August 2016 by University Health Network, Toronto
Sponsor:
Information provided by (Responsible Party):
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT01914510
First received: July 11, 2013
Last updated: August 5, 2016
Last verified: August 2016
  Purpose

This is a phase 2 study to see how useful, safe, and tolerable an investigational drug called ENMD-2076 is in treating patients with ovarian clear cell carcinomas.

ENMD-2076 is an oral drug that works by blocking certain enzymes called Aurora A and tyrosine kinase from working. These enzymes are needed for cells to divide including cancer cells. ENMD-2076 also works by stopping the growth of new blood vessels which would provide the tumor with nutrients for it to grow. It is believed that by blocking Aurora A and tyrosine kinase enzymes from working and stopping new blood vessels from growing, the tumors may stop growing or shrink.


Condition Intervention Phase
Ovarian Clear Cell Carcinoma Drug: ENMD-2076 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas

Resource links provided by NLM:


Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • Number of patients with and without disease progression at 6 months after treatment [ Time Frame: 2 years ]
  • Percentage of patients with complete or partial response [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Length of response in patients treated with ENMD-2076 [ Time Frame: 2 years ]
  • Levels of certain proteins and gene expression compared to patient outcome following treatment [ Time Frame: 2 years ]

Estimated Enrollment: 36
Study Start Date: September 2013
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ENMD-2076
ENMD-2067 will be taken orally at a dose of 275 mg, once a day, everyday. Patients with a body surface area of less than 1.65 m2 will receive a starting dose of 250 mg, once a day, everyday.
Drug: ENMD-2076

Detailed Description:
During the study, participants will be asked to take ENMD-2076 once a day, everyday. Every 28 days will be called a cycle. While receiving the study drug, participants will be asked to visit the clinic for tests and procedures. During Cycle 1, participants will be asked to visit the clinic about once a week and during Cycle 2 and future cycles, participants will be asked to visit the clinic on days 1 and 15. As a part of the study, tumor tissue (archival and fresh tumor biopsy) will be taken for biomarker research. When participants stop the study drug, they will be asked to have an end of study drug visit.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have histologically documented diagnosis of ovarian clear cell carcinoma.
  • Any number of prior chemotherapy regimens will be allowed but must include 1 line of platinum based therapy, and may include chemotherapy, biologics or other targeted therapies (except for Aurora A targeted therapies).
  • Meet RECIST criteria (version 1.1) within 28 days of start of treatment by having measurable disease defined as one or more lesions that can be accurately measured in one or more dimensions. Areas of previous radiation may not serve as measurable disease unless there is evidence of progression post radiation.
  • At time of registration, if the patient has had previous treatment it must have been at least 4 weeks since major surgery or radiation therapy; four weeks from any other previous anti-cancer therapy including biologics. Patients must have recovered from their treatment-related events with the exception of alopecia.
  • Are ≥18 years of age
  • Have clinically acceptable laboratory screening results within certain limits specified below:

    • AST and ALT ≤ 2.5 times upper limit of normal (ULN) or less than or equal to 5 times ULN if liver metastases are present
    • Total bilirubin ≤ 1.5 x ULN
    • Creatinine ≤ 1.5 x UL
    • Absolute neutrophil count ≥ 1500 cells/mm
    • Platelets ≥ 150,000/mm3
    • Hemoglobin ≥ 9.0 g/dl
  • Have an ECOG performance status of ≤ 2
  • Women of child-producing potential must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least 30 days after the last administration of study medication. A serum pregnancy test within 72 hours prior to the initiation of therapy will be required for women of childbearing potential.
  • Have the ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments.
  • Able to tolerate oral medication.

Exclusion Criteria:

  • Women who are pregnant or nursing
  • Have active, acute, or chronic clinically significant infections or bleeding.
  • Have uncontrolled hypertension (systolic blood pressure greater than 150mmHg or diastolic blood pressure greater than 100mmHg); or history of congestive heart failure (equal to or greater than Grade 2).
  • Have active angina pectoris, stroke, previous myocardial infarction within the past 12 months and not clinically stable, or any other pre-existing uncontrolled cardiovascular condition.
  • Have chronic atrial fibrillation or QTc interval corrected for heart rate of greater than 470 msec.
  • Have additional uncontrolled serious medical or psychiatric illness.
  • Require therapeutic doses of anti-coagulation with warfarin or other coumarin derivatives. However, treatment with low molecular weight heparin (LMWH) is allowed.
  • Known CNS metastases
  • Have any medical condition that would impair the administration of oral agents including recurrent bowel obstructions, inflammatory bowel disease or uncontrolled nausea, vomiting or diarrhea
  • Have persistent 2+ protein by urinalysis (patients with 2+ proteinuria that have a spot protein:creatinine ratio of less than 0.3 may be enrolled) or a history of nephrotic syndrome
  • Have an active or history of additional malignancy which in the opinion of the study doctor would make assessment of outcome difficult.
  • Require treatment with drugs known to be potent inducers or inhibitors of CYP3A4 at the time of registration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01914510

Contacts
Contact: Amit Oza, M.D. 416-946-288

Locations
Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Prafull Ghatage, M.D.    403-521-3721      
Principal Investigator: Prafull Ghatage         
Cross Cancer Institute Not yet recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Katia Tonkin, M.D.    780-432-8514      
Principal Investigator: Katia Tonkin, M.D.         
British Columbia Cancer Agency Recruiting
Vancouver, Alberta, Canada, V5Z 4E6
Contact: Anna Tinker, M.D.    604-877-6000      
Principal Investigator: Anna Tinker         
Canada, Ontario
London Regional Cancer Program Not yet recruiting
London, Ontario, Canada, N6A 4L6
Contact: Stephen Welch, M.D.    519-685-8640      
Principal Investigator: Stephen Welch, M.D.         
Ottawa Regional Cancer Centre Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Johanne Weberpals, M.D.    519-737-8899 ext. 76462      
Principal Investigator: Johanne Weberpals, M.D.         
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Amit Oza, M.D.    416-946-2818      
Principal Investigator: Amit Oza, M.D.         
Sponsors and Collaborators
University Health Network, Toronto
Investigators
Principal Investigator: Amit Oza, M.D. Princess Margaret Cancer Centre
  More Information

Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT01914510     History of Changes
Other Study ID Numbers: ENMD-2076-OCC
Study First Received: July 11, 2013
Last Updated: August 5, 2016

Keywords provided by University Health Network, Toronto:
ovarian
cancer
clear cell
ENMD-2076
oral
capsule

Additional relevant MeSH terms:
Carcinoma
Adenomyoepithelioma
Adenocarcinoma, Clear Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Complex and Mixed
Adenocarcinoma

ClinicalTrials.gov processed this record on June 26, 2017